Novacyt eyes M&A as it names corporate development officer

Novacyt, AIM’s star performer of last year has reshuffled its finance executives and exec management as it looks to continue its growth trajectory this year.

In an update to the market, the international diagnostics business revealed that it has hired a new Chief Financial Officer, while its existing Chief Financial Officer will move into a more strategic role as Chief Corporate Development Officer.

James McCarthy will be the new CFO, joining from Flint Group, while current CFO Anthony Dyer will become the new Chief Corporate Development Officer – a role that is traditionally synonymous with mergers and acquisitions.

Commenting on the appointments was Novacyt CEO Graham Mullis who noted:

I would also like to take this opportunity to thank Anthony personally for the key role he has played in helping transform Novacyt into a leading diagnostics developer and manufacturer. His new, important role reflects the Company’s growth strategy, which includes selective potential M&A to supplement organic growth initiatives. I look forward to working with Anthony and James as part of an expanded executive team.”

The Novacyt share price is currently at 855p.

McCarthy will become a board member.

Let's Talk

Argo Blockchain Share Price Predi …0.80p :D. Just kidding. Will rise after placing, always do. No rea … Read More
Remote Monitored Systems shares - …Hahahaha. The RMS patrol are still out and about - just sell out o … Read More
What shares is everyone buying no …Cine I know it's a risky but its got a lot of volume. BP on t … Read More
The rise of the COVID stocks revi …Tough shout with SNG but it doesn't seem to have long to get … Read More
Massive ODX overreaction?Seems like someone has a big axe to grind with the UK RTC or the g … Read More
Hey, profit awaits! Free Sharebuyers Newsletter

Receive the hottest share tips and information you can profit from. Twitter: @ShareBuyers.